The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
ORGANIZATION
Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
Major pharma trade organizations of Japan, the US, and Europe on November 15 issued a joint statement calling on Prime Minister Shigeru Ishiba’s new administration to abolish the FY2025 “off-year” drug price revision and create a new national biopharmaceutical strategy.…
To read the full story
Related Article
ORGANIZATION
- Off-Year Revisions Need Careful Assessments and Discussions: Chuikyo JMA Rep
December 20, 2024
- JPMA to Continue Seeking Repeal of Off-Year Revisions: Exec
December 20, 2024
- JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
- Japan Citizens’ Group Opposes RWD-Only Drug Submissions
December 16, 2024
- EFPIA Japan Issues Joint Statement for Resolving Drug Lags/Losses
December 12, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…